News | News By Subject | News by Disease News By Date | Search News

Growth hormone replacement News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Phase III Flop for Pfizer (PFE)'s Drug Partner Opko Health (OPK)     1/3/2017
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
BioPartners GmbH and LG Life Sciences, Ltd. Present Positive Phase 3, Twenty-Four Months Efficacy and Safety Data for Sustained Release Recombinant Human Growth Hormone (LB03002) Given to Children with Growth Hormone Deficiency     9/27/2011
AEterna Zentaris (AEZS) Announces Favorable Top-Line Results of Completed Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency     8/30/2011
Japan Approves First Generic Biotech Drug Somatropin From Novartis AG     6/26/2009
BioPartners Holdings AG: Clinical Phase III Trial Data Demonstrate Valtropin®'s Safety and Efficacy     8/14/2007
Serono, Inc. (SRA) Announces Results From Pivotal Phase III Clinical Trial Of Its Proprietary Recombinant Human Growth Hormone In The Treatment Of HARS At The XVI International AIDS Conference; Trial Achieves Goal     8/18/2006
Altus Pharmaceuticals Inc. (ALTU) Updates Plans For Initiation Of Phase III Clinical Trials For ALTU-135 And ALTU-238; Sites Trial Delays; Stock Falls 33%     7/25/2006
FDA Approves Insmed Incorporated (INSM)'s Orphan Drug, IPLEX, For The Treatment Of Severe Primary IGF-1 Deficiency; The First Once-Daily Therapy For The Treatment Of Severe Primary IFG-1 Deficiency     12/13/2005
FDA Grants Priority Review For Insmed Incorporated's (INSM) NDA For SomatoKine For The Treatment of Growth Hormone Insensitivity Syndrome     4/13/2005
Genentech, Inc. (DNA) And Ipsen Agree To Develop Sustained-Release Formulations Of Recombinant Human Growth Hormone     3/21/2005
FDA Accepts For Review Insmed Incorporated's (INSM) NDA For SomatoKine For The Treatment Of Growth Hormone Insensitivity Syndrome     3/10/2005
Novo Nordisk (NVO) Release: A New Indication For Norditropin(R) (Somatropin [rDNA] Injection)     11/4/2004

News from Around the Web

Press Releases
Ascendis Announces Publication Of Comprehensive Results From Randomized, Active-Controlled Phase 2 Trial Of Once-Weekly Transcon Growth Hormone In Pediatric Patients     2/17/2017
AEterna Zentaris (AEZS) Crashes on Disappointing Phase III Data     1/5/2017
Genexine Co. Ltd. Granted FDA Orphan Drug Designation For GX-H9 In Growth Hormone Deficiency     11/16/2016
AEterna Zentaris (AEZS) Completes Patient Recruitment For Confirmatory Phase III Trial Of Macrilen     10/26/2016
BioMarin (BMRN) Presents Vosoritide Data In Achondroplasia At American Society of Human Genetics 2016 Meeting     10/19/2016
Versartis (VSAR) Presents Efficacy, Safety, Metabolic And Adherence Data For Somavaratan In Oral Session At The International Congress Of Endocrinology     9/6/2016
Opko Health (OPK) To Present Long-Acting Human Growth Hormone (HGH-CTP) Phase II Pediatric Growth Hormone Deficiency Data At The 55th Annual Meeting Of The European Society For Pediatric Endocrinology     9/6/2016
Ascendis Pharma A/S Announces R&D Update To Review Expanded Pipeline And Long-Term Strategic Outlook     8/16/2016
Ascendis Pharma A/S Initiates Phase 3 Registration Trial For TransCon Growth Hormone In Children With Growth Hormone Deficiency     8/11/2016
Ascendis Pharma A/S Announces TransCon Growth Hormone Oral And Poster Presentations At ENDO 2016     4/4/2016
Versartis, Inc. (VSAR) Presents Confirmatory 18-Month Adherence Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ENDO Annual Meeting     4/1/2016
AEterna Zentaris (AEZS) To Participate In 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities     2/2/2016
AEterna Zentaris (AEZS) Concludes Successful Meeting Of Clinical Investigators For Confirmatory Phase III Trial Of Macrilen     1/19/2016
Cobra Biologics Ltd. Appointed By University of Sheffield To Advance Novel Fusion Protein Technology Into Phase 1 Clinical Trials     11/23/2015
AEterna Zentaris (AEZS) Announces First Patient Enrolled For Confirmatory Phase 3 Trial Of Macrilen For The Evaluation Of AGHD     11/19/2015